Internal Medicine, Infectious Disease · Dallas, TX
NPI
1831155787
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
3409 Worth St, 710
Dallas, TX, 75246
Phone (214) 823-2533
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
128,188 services
Medicare patients, 2024
709
Average age 73
Drug cost, 2024
$2.3M
1,816 prescriptions
Company payments, 2025
$7,737
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mezgebe Berhe was code J0485 (injection, belatacept, 1 mg), 48,550 times for 13 patients. In total Mezgebe Berhe billed 128,188 services in 61 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0485 Injection, belatacept, 1 mg | Office | 48,550 | 13 | $3.01 | $146K |
| J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 7,380 | 11 | $38.59 | $285K |
| J0897 Injection, denosumab, 1 mg | Office | 7,080 | 97 | $19.66 | $139K |
| 99232 Hospital E&M - Subsequent | Facility | 851 | 311 | $61.15 | $52K |
| 99233 Hospital E&M - Subsequent | Facility | 465 | 196 | $92.57 | $43K |
| 99214 Office E&M - Established | Office | 401 | 167 | $85.27 | $34K |
| 96365 Intravenous Infusion, Hydration | Office | 386 | 88 | $45.69 | $18K |
| 96372 Injection Administration | Office | 264 | 117 | $9.07 | $2,394 |
| 96366 Intravenous Infusion, Hydration | Office | 202 | 11 | $15.31 | $3,093 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 175 | 35 | $3.38 | $591 |
| 99223 Hospital E&M - Initial | Facility | 158 | 149 | $133.59 | $21K |
| 96375 Injection Administration | Office | 116 | 11 | $11.53 | $1,337 |
| 99222 Hospital E&M - Initial | Facility | 107 | 101 | $101.17 | $11K |
| J1335 Injection, ertapenem sodium, 500 mg | Office | 100 | 12 | $9.07 | $907 |
| 96413 Chemotherapy Administration | Office | 96 | 22 | $90.65 | $8,702 |
By year: 2022 $2.2M for 212,388 services; 2023 $2.3M for 202,015 services; 2024 $1.2M for 128,188 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mezgebe Berhe prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 149 prescriptions and refills. In total Mezgebe Berhe wrote 1,816 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 149 | 151 | 21 | $589K |
| Daptomycin Generic | 141 | 142 | 43 | $90K |
| Meropenem Generic | 106 | 107 | 28 | $25K |
| Ceftriaxone Ceftriaxone Sodium | 95 | 96 | 31 | $6,882 |
| Ertapenem Ertapenem Sodium | 83 | 84 | 27 | $35K |
| Vancomycin Hcl Generic | 62 | 62 | 17 | $5,335 |
| Fosfomycin Tromethamine Generic | 60 | 63 | 18 | $13K |
| Tivicay Dolutegravir Sodium | 60 | 60 | Under 11 | $165K |
| Dovato Dolutegravir Sodium/Lamivudine | 54 | 54 | Under 11 | $159K |
| Doxycycline Hyclate Generic | 50 | 58 | 16 | $1,206 |
| Minocycline Hcl Generic | 43 | 48 | 12 | $1,115 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 41 | 41 | Under 11 | $162K |
| Cefepime Hcl Generic | 36 | 36 | 17 | $11K |
| Azithromycin Generic | 34 | 44 | 11 | $474 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 32 | 41 | 11 | $354 |
Brand drugs: 572 claims; generic drugs: 1,244 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mezgebe Berhe $7,737 ($7,737 in general payments such as food, travel and fees) from 16 companies. The largest payer was Mannkind Corporation with $4,676.
| Company | Payments | Amount |
|---|---|---|
| Mannkind Corporation MNKD | 2 | $4,676 |
| ViiV Healthcare Company GSK | 27 | $1,840 |
| Gilead Sciences, Inc. GILD | 8 | $437 |
| Insmed, Inc. INSM | 10 | $265 |
| Merck Sharp & Dohme LLC MRK | 4 | $106 |
| Shionogi Inc 4507.T | 6 | $101 |
| Pfizer Inc. PFE | 4 | $80.02 |
| Astellas Pharma US Inc 4503.T | 3 | $63.19 |
| Ferring Pharmaceuticals Inc. | 2 | $52.57 |
| Aimmune Therapeutics, Inc. | 2 | $37.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.